SINGAPORE – Media OutReach Newswire – December 22, 2023 – Novo Nordisk Pharma (Thailand) Ltd. emerged triumphant by winning three prestigious accolades at the Asia Pacific Enterprise Awards (APEA) 2023 in Thailand on August 25. The leading healthcare company specializing in diabetes care has been recognized with awards in the Inspirational Brand, Fast Enterprise and Corporate Excellence categories. This remarkable feat not only highlights Novo Nordisk’s commitment to excellence, but also highlights its significant contributions to Thailand’s healthcare sector.
Founded in Denmark in 1923, Novo Nordisk has a rich history. The company started as a small insulin manufacturer and has since grown into an international pharmaceutical company specializing in diabetes care and the treatment of serious chronic diseases. Novo Nordisk is committed to driving change to defeat serious chronic diseases through innovative solutions and treatments. In 1983, Novo Nordisk Pharma (Thailand) Ltd. in particular has been in business for 40 years, with more than 260 employees devoting all their efforts to strengthening the care of diabetes and other serious chronic diseases in Thailand throughout this period.
Novo Nordisk Pharma (Thailand) Ltd. believes that its success is the result of its commitment to creating a healthier and more sustainable world for every generation. Companies are attracted to the Novo Nordisk Pharma (Thailand) Ltd. brand because it has built a reputation for consistently providing safe, high-quality products that make a difference to people suffering from health conditions such as diabetes , obesity and other serious health problems. chronic diseases.
In addition to the company’s commitment to defeating serious chronic diseases through innovative solutions and treatments, Novo Nordisk Pharma (Thailand) Ltd.’s reputation has been recognized. as a leader in healthcare innovation relies on sustainable business. For over 40 years, Novo Nordisk has provided essential medications and resources to diabetes patients in Thailand. His unwavering commitment to patient-centered care has impacted countless people across the country. Novo Nordisk’s research and development efforts have led to breakthrough treatments such as GLP1 and insulin that have transformed diabetes care in Thailand. His commitment to pushing the boundaries of medical science and patient care has left an indelible mark on the healthcare industry.
The company’s brand also reflects its corporate responsibility to make a positive impact on the world. The strong commitment of Novo Nordisk Pharma (Thailand) Ltd. towards ethical values, social responsibility and environmental sustainability sets the company apart from others and inspires businesses around the world to follow its example. Novo Nordisk Pharma (Thailand) Ltd. is committed to driving change to defeat serious chronic diseases through innovative solutions and treatments.
Additionally, all employees of Novo Nordisk Pharma (Thailand) Ltd. are proud of their company’s heritage and excited about its future. They are dedicated to making a positive impact on the world, believing that everyone has a role to play in creating a healthier world. In the future, Novo Nordisk Pharma (Thailand) Ltd. aims to continue to drive change and improve the health and well-being of all Thais.
The issuer is solely responsible for the content of this announcement.
